ACST Overview
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Loading chart...
The current price of ACST is 0 USD — it has increased 0 % in the last trading day.
Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.
Wall Street analysts forecast ACST stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACST is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Acasti Pharma Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.
Acasti Pharma Inc. EPS for the last quarter amounts to -0.30 USD, decreased -30.23 % YoY.
Acasti Pharma Inc (ACST) has 4 emplpoyees as of January 23 2026.
Today ACST has the market capitalization of 28.00M USD.
